Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

24-Month assessment of respiratory function in patients hospitalized for severe SARS-CoV-2 pneumonia: a follow-up study.

Internal and emergency medicine·2025
Same author

Standardized bilateral thoracic ultrasound image comparison as a tool for the diagnosis of pneumothorax: a pilot exploratory study.

Journal of ultrasonography·2025
Same author

Long-term alveolar-capillary diffusion impairments after severe SARS-CoV-2 pneumonia.

Annals of medicine·2025
Same author

What is worth measuring in patients with COPD?

Multidisciplinary respiratory medicine·2025
Same author

Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial.

The Lancet. Respiratory medicine·2023
Same author

Short-Term Evolution of Nutritional Status in Patients with Idiopathic Pulmonary Fibrosis.

Annals of the American Thoracic Society·2023

Related Experiment Video

Updated: May 24, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Lung function decline in COPD.

Claudio Tantucci1, Denise Modina

  • 1Unit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy. tantucci@med.unibs.it

International Journal of Chronic Obstructive Pulmonary Disease
|February 29, 2012
PubMed
Summary
This summary is machine-generated.

Chronic obstructive pulmonary disease (COPD) lung function decline accelerates in earlier stages, contrary to previous beliefs. Early intervention is crucial for impacting COPD

Keywords:
FEV1chronic obstructive pulmonary diseasedeclineforced expiratory volume in 1 second

More Related Videos

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Related Experiment Videos

Last Updated: May 24, 2026

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
04:03

Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians

Published on: September 27, 2024

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity
07:13

Phenotyping Mouse Pulmonary Function In Vivo with the Lung Diffusing Capacity

Published on: January 6, 2015

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Clinical Trials

Background:

  • The Fletcher and Peto study suggested a slow initial decline in Forced Expiratory Volume in 1 second (FEV1) for chronic obstructive pulmonary disease (COPD), accelerating with disease progression.
  • Previous understanding indicated a slower FEV1 decline in early-stage COPD.

Purpose of the Study:

  • To re-evaluate the natural history of lung function decline in COPD across different disease severity stages.
  • To assess FEV1 decline rates in patients within the placebo arms of recent clinical trials.

Main Methods:

  • Review of spirometric data from COPD patients in placebo-controlled clinical trials.
  • Classification of patients into Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages based on airflow obstruction severity.

Main Results:

  • Mean FEV1 decline rates in GOLD stages II and III were 47-79 mL/year and 56-59 mL/year, respectively.
  • Mean FEV1 decline in GOLD stage IV was less than 35 mL/year.
  • Limited data exists for GOLD stage I, but initial findings suggest accelerated decline in early COPD phases.

Conclusions:

  • Lung function loss, specifically expiratory airflow reduction, appears more rapid in the initial phases of COPD.
  • Targeting treatments towards earlier stages of COPD is logical for potentially impacting the disease's natural history.